Patent intelligence · US
US 12364775
Viral vectors for cancer therapy
Viral vectors for cancer therapy
Patent details — US 12364775
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 22, 2025
- Expiration
- Jul 17, 2045
- Applicant
- Krystal Biotech, Inc.
- Claims
- 32
- CPC classes
- A61K, A61K35/763, A61K38/193, A61K38/2013
Quick answer
US 12364775 (Viral vectors for cancer therapy) is held by Krystal Biotech, Inc.. Status: granted. Granted Jul 22, 2025. Expires Jul 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Krystal Biotech, Inc.
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61K, A61K35/763, A61K38/193, A61K38/2013, A61K38/208, A61K48/0066
More from Krystal Biotech, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12128122
Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic
granted -
US 11918660
Viral vectors for cancer therapy
granted -
US 11865148
Methods of delivering transgenes to the eye
granted -
US 11779660
Viral vectors for cancer therapy
granted -
US 11717547
Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
granted -
US 11642384
Compositions and methods for the treatment of Netherton Syndrome
granted -
US 11185564
Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
granted
Frequently asked questions
What is US patent 12364775?
US 12364775 (Viral vectors for cancer therapy) is held by Krystal Biotech, Inc.. Status: granted. Granted Jul 22, 2025. Expires Jul 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12364775?
Krystal Biotech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 12364775 expire?
Our index shows an expiration date of Jul 17, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.